Affinity Asset Advisors LLC Trims Position in Rezolute, Inc. (NASDAQ:RZLT)

Affinity Asset Advisors LLC trimmed its stake in Rezolute, Inc. (NASDAQ:RZLT) by 7.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,575,000 shares of the company’s stock after selling 125,000 shares during the period. Rezolute comprises 1.0% of Affinity Asset Advisors LLC’s holdings, making the stock its 27th biggest holding. Affinity Asset Advisors LLC’s holdings in Rezolute were worth $7,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of RZLT. State Street Corp increased its holdings in Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after purchasing an additional 13,000 shares during the period. XTX Topco Ltd raised its holdings in shares of Rezolute by 67.4% in the third quarter. XTX Topco Ltd now owns 56,375 shares of the company’s stock valued at $273,000 after acquiring an additional 22,704 shares in the last quarter. MML Investors Services LLC purchased a new stake in Rezolute in the third quarter worth about $57,000. Geode Capital Management LLC grew its holdings in Rezolute by 39.0% during the 3rd quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock worth $2,385,000 after acquiring an additional 137,905 shares in the last quarter. Finally, Virtu Financial LLC increased its position in Rezolute by 58.0% during the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company’s stock valued at $126,000 after purchasing an additional 9,551 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on RZLT shares. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Thursday, February 13th. JMP Securities upped their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Rezolute in a research note on Monday, February 10th. Finally, Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Rezolute presently has an average rating of “Buy” and a consensus price target of $24.38.

Rezolute Price Performance

Shares of RZLT stock opened at $2.57 on Tuesday. The business has a fifty day moving average of $3.65 and a 200 day moving average of $4.54. The firm has a market capitalization of $155.57 million, a price-to-earnings ratio of -2.11 and a beta of 0.97. Rezolute, Inc. has a 1 year low of $2.22 and a 1 year high of $6.19.

Rezolute (NASDAQ:RZLT) last released its earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. As a group, equities research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Insider Transactions at Rezolute

In related news, CFO Daron Evans acquired 10,000 shares of the stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the transaction, the chief financial officer now owns 237,900 shares in the company, valued at approximately $687,531. This trade represents a 4.39 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nevan C. Elam bought 12,302 shares of the business’s stock in a transaction dated Thursday, March 27th. The shares were purchased at an average cost of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. This represents a 5.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 39,060 shares of company stock worth $130,694 over the last 90 days. 18.39% of the stock is currently owned by company insiders.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.